Roivant Sciences’ subsidiary, Pulmovant, has secured global rights to mosliciguat, an inhaled sGC activator for pulmonary hypertension (PH). Initial Phase 1b trial results show significant reductions in pulmonary vascular resistance, highlighting the potential of this therapy for PH-ILD patients.
Results for: Pulmonary Hypertension
Liquidia Corporation’s stock took a significant hit after the FDA granted tentative approval to their drug YUTREPIA for treating pulmonary hypertension. The approval comes with a catch – regulatory exclusivity granted to United Therapeutics for Tyvaso DPI, which delays YUTREPIA’s full market entry until 2025. Liquidia plans to challenge this decision.